Yvonne Diaz
LightNews LightNews
banner
yvonnediaz.bsky.social
Yvonne Diaz
@yvonnediaz.bsky.social
410 followers 450 following 72 posts
Comms professional, mum to twin teenage sons & a dog. Living with stage 4 ALK lung cancer. Advocate for research for those living with lung cancer & those who no longer have a voice.

Co-founder & Chair, Oncogene Cancer Research
Board member, ALK Positive
Posts Replies Media Videos
Reposted by Yvonne Diaz
edmonstone.net
I was honoured to spend a few hours recently talking with
@yvonnediaz.bsky.social from @oncogenecancer.bsky.social
about my lung cancer experiences. This first part is about my initial diagnosis and the start of my treatment. More to come shortly! youtu.be/FZsbfkloPyM?...
Duncan was 49, healthy. One day he had a seizure after work. It was stage 4 lung #cancer | #podcast
YouTube video by Oncogene Cancer Research
youtu.be
October 26, 2025 at 5:18 PM
yvonnediaz.bsky.social
This morning’s DeLLphi presentation @myesmo.bsky.social brings so much hope to our #lungcancer community. Love seeing fresh hope for those with small cell lung cancer. #ESMO25
Image of presenter Dr Martin Werner at ESMO presenting data on climate he delllphi study.
October 18, 2025 at 7:49 AM
Reposted by Yvonne Diaz
oncogenecancer.bsky.social
Cancer #cachexia is an urgent but under-recognised challenge in lung cancer. At @LUNGevity’s #ILCSC25, @yvonnediaz.bsky.social will join Dr Richard Dunne to highlight hope underway from @cancergrand.bsky.social Team CANCAN.

Sign up 👇

reg.eventmobi.com/ilcsc2025/regi…#LCSMSM
September 16, 2025 at 9:44 AM
Reposted by Yvonne Diaz
alkpositive.bsky.social
🌍 The 2025 ALK+ Summit brought together our community from 30 countries — united in one mission: accelerating research and supporting ALK-positive lives.

💙 Together, we are stronger.

👉 Stay connected for ALK Summit 2026: mailchi.mp/alkpositive/...

#ALKPositive #StrongerTogether
September 16, 2025 at 6:20 PM
yvonnediaz.bsky.social
Lung cancer is increasingly being diagnosed in younger, fit women with no smoking history - like Sarah & Becca.

As Drs Cecilia Pompili & Alex Georgiou say, we need greater awareness, & more research so that women are seen, heard, and diagnosed sooner.

theguardian.com/society/2025/s…#lcsmsm
Photo of a lung cancer patient called Sarah who was diagnosed with lung cancer at age 40 A photo of Sarah holding up the guardian newspaper which features an article of her being diagnosed with lung cancer despite never having smoked and being young and a marathon
September 16, 2025 at 9:04 AM
Reposted by Yvonne Diaz
alkpositive.bsky.social
Congratulations to friends at Nuvalent on the exciting and pivotal #ARROS1 data released @iaslc.bsky.social #WCLC25. Proud to continue to collaborate on outcomes for our patient community globally. 💙
#LCSM
September 10, 2025 at 8:40 PM
Reposted by Yvonne Diaz
drcamidge.bsky.social
After three years I feel ready to enter a new phase of patient empowerment by publicly disclosing my own disgnosis. This went live today and all good. news.cuanschutz.edu/cancer-cente...
World Lung Cancer Expert Diagnosed with Advanced Lung Cancer
D. Ross Camidge, MD, PhD, has spent his career fighting lung cancer. In 2022, that fight turned personal when he received a diagnosis of his own.
news.cuanschutz.edu
September 8, 2025 at 4:01 PM
Reposted by Yvonne Diaz
oncogenecancer.bsky.social
Our cofounder @janclark1.bsky.social & her daughter Amy shared their story on BBC Radio highlighting why more research is vital & how our first Charity Ball on 1 Nov will raise funds for this vastly underfunded cancer.

Check it out👇📷
static1.squarespace.com/static/65ca0...

#LCSM
Photos of Jan Clark, our co-founder, with her daughter Amy who was diagnosed at age 20 which stage four lung cancer. They’re standing next to BBC radio presenter. John Darvall
September 5, 2025 at 12:54 PM
Reposted by Yvonne Diaz
oncogenecancer.bsky.social
Surgery isn’t usually offered for stage 4 #lungcancer.

Steve, diagnosed w stage 4 ALK+ in 2020, believed it could help prevent resistance. After targeted therapy shrank his tumour, he fought for surgery & got it.

Read his story + our patient info: oncogeneresearch.org/surgery
#LCSM
August 14, 2025 at 8:24 AM
Reposted by Yvonne Diaz
alkpositive.bsky.social
✨ What a weekend!✨

Our 2025 ALK+ Summit wrapped up today — but the connections, knowledge & hope keep going strong. Thank you for showing up & reminding us we’re #StrongerTogether.

Stay tuned for more moments from this unforgettable weekend! 💙

#ALKSummit25 #LCSM
July 21, 2025 at 1:11 AM
yvonnediaz.bsky.social
The ALK+ Summit is truly one of the most anticipated events for our ALK cancer community. Not everyone can travel to San Diego to join, but worth watching online. We will also post all videos after the event too.

Registration link below 👇
alkpositive.bsky.social ALK Positive Inc. @alkpositive.bsky.social · Jul 16
✨ 3 days to go!

Our #ALKSummit25 is more than a conference — it’s hope, connection & the fuel that powers research forward.
 
Last year was unforgettable. This year? Even bigger. 💙
 
📅 July 18–20

Join us virtually: secure.qgiv.com/for/alksummit2…

Fantastic speakers & agenda#LCSMSM
July 16, 2025 at 11:47 AM
Reposted by Yvonne Diaz
oncodaily.bsky.social
Oncogene Cancer Research - Talk of Hope Podcast on Liquid Biopsy and Speed to Lung Cancer Diagnosis
@oncogenecancer.bsky.social
@yvonnediaz.bsky.social
@prof-ali-g.bsky.social

oncodaily.com/blog/talk-of...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedOnc #MedNews #TalkofHope #LungCancer
Talk of Hope Podcast on Liquid Biopsy and Speed to Lung Cancer Diagnosis - Oncogene Cancer Research - OncoDaily
Talk of Hope Podcast on Liquid Biopsy and Speed to Lung Cancer Diagnosis - Oncogene Cancer Research / Alastair Greystoke, cancer, Liquid Biopsies, Lung
oncodaily.com
July 5, 2025 at 11:05 PM
Reposted by Yvonne Diaz
oncogenecancer.bsky.social
We’re proud to donate £10,425 to @icr.ac.uk to advance oncogene-driven lung cancer research, supporting the vital work of Dr Paul Huang.

This is just the start — stay tuned for more big research plans. 💙🔬

oncogeneresearch.org/icr-donation

#LCSM
Screen grab of our co-founders Yvonne Diaz and Jan Clark with the OCR’s Dr Paul Huang. We’re thrilled to announce a £10,425 donation to the Institute of Cancer Research (ICR) to support vital work into oncogene-driven lung cancers, including research led by Dr Paul Huang’s team. This donation builds on the £90,000+ already contributed by our co-founders and community to help establish a cross-biomarker biobank and support world-class research at ICR. A huge thank you to our incredible marathoners — 🏃‍♀️ Christina Roberts 🏃‍♀️ Ruth Price 🏃‍♀️ Aude-Aline Eugene — for going the distance and raising these essential funds. You’ve inspired us all. And this is just the beginning. Stay tuned — we’ve got more big plans to support research on the way. 🔬💙 #OncogeneCancerResearch #ICR #LungCancerAwareness #PatientLedResearch #BiomarkerDriven #MarathonForResearch #ThankYou
July 9, 2025 at 9:44 AM
Reposted by Yvonne Diaz
alkpositive.bsky.social
Amy, Seth, Amanda & Nancy are powered by faith, family & the fight for more research.

This #ALKPositive Awareness Month, they’re taking action to raise $500K for lifesaving breakthroughs.

Join the #PoweredByPatients movement 👉 secure.qgiv.com/event/alkpos... #APAM
June 16, 2025 at 2:45 PM
Reposted by Yvonne Diaz
alkpositive.bsky.social
🎥 Missed our #APAM kickoff ALKtALK?

Dr. Jesse Boehm shares how @break_cancer is advancing bold ALK+ research & how we’re helping fund it.

We’re raising $500K to continue to project the work at BTC & others like it.

🔗 Watch now youtu.be/GxrUsGIAFUs
#PoweredByPatients #lcsm
June 12, 2025 at 1:35 PM
Reposted by Yvonne Diaz
oncogenecancer.bsky.social
📢 Help us understand the emotional toll of #lungcancer.

With @lungcancereurope.bsky.social & 46 orgs, we’re surveying patients & caregivers across Europe to explore the mental health impact of a diagnosis.

🧠 Your voice can shape better support.

🔗 surveymonkey.com/r/LuCESurvey20…#LCSMSM
💬 Help us understand the emotional toll of lung cancer. Have you or a loved one been impacted by lung cancer? We’re running a survey across Europe to explore the psychological impact of a lung cancer diagnosis—on both patients and caregivers. 🧠 We want to hear directly from you. What’s been hardest to cope with? What support (if any) have you received? What’s missing? 📢 Your voice matters. By sharing your experience, you can help improve mental health services for others affected by this disease. 👉 Open to people diagnosed with lung cancer and their caregivers (excluding healthcare professionals) living in Europe. Take the survey here
June 5, 2025 at 11:27 AM
yvonnediaz.bsky.social
Promising signals from the ALEK-B ph 2 trial: combining alectinib w bevacizumab achieved 97.1% 12-mo PFS & median PFS of 39.6 months in ALK+ #NSCLC. Intracranial control also notably strong.

Could this combo help overcome resistance in more aggressive ALK variants?
#research #lungcancer
The article titled "Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial" presents findings from a clinical study evaluating the efficacy and safety of combining alectinib, an ALK tyrosine kinase inhibitor, with bevacizumab, an anti-angiogenic agent, in treating advanced ALK-rearranged non-small cell lung cancer (NSCLC). Nature Here are five key takeaways from the study: Enhanced Progression-Free Survival (PFS): The combination therapy achieved a 12-month PFS rate of 97.1% and a 36-month PFS rate of 64.2%, indicating a potential improvement over historical data for alectinib monotherapy. Nature High Overall Response Rate (ORR): All 41 patients in the study responded to the treatment, with 87.8% achieving partial responses and 12.2% achieving complete responses, resulting in a 100% ORR. Nature Intracranial Efficacy: The therapy demonstrated significant activity in the central nervous system, with a 36-month intracranial PFS rate of 87.8%, suggesting effectiveness in preventing or delaying brain metastases. Nature Manageable Safety Profile: While 46.3% of patients experienced grade 3–4 adverse events, including proteinuria and hepatotoxicity, no fatal events were reported, and quality of life improved over the course of treatment. Nature Need for Further Research: The promising results support the rationale for conducting randomized controlled trials to compare this combination therapy directly with existing standard treatments and to further assess its benefits and risks. Nature These findings suggest that the combination of alectinib and bevacizumab may offer a potent first-line treatment option for patients with advanced ALK-rearranged NSCLC, warranting further investigation in larger, randomized studies
May 18, 2025 at 11:30 AM
Reposted by Yvonne Diaz
oncogenecancer.bsky.social
Understanding cultural norms in cancer care is key.

Aurora Lucas, an advocate living w EGFR #lungcancer, shares how she went from staying silent—out of fear of being disrespectful — to speaking up in this editorial with Dr @lungoncdoc.bsky.social.

👇 openworks.mdanderson.org/aceqi/vol1/i...
#LCSM
Summary of an article: This editorial emphasizes that patient education is a vital, not optional, part of lung cancer care. It argues that when patients are equipped with clear, culturally responsive, and accessible information, they are better prepared to engage in their treatment, make informed decisions, and adhere to care plans. Key insights include: Understanding the disease: Lung cancer is complex, and patients benefit from education tailored to different learning styles—visual aids, plain language, and culturally sensitive approaches are critical. Shared decision-making: Empowering patients to speak up and collaborate with providers leads to better care alignment with personal values, especially when patients overcome cultural norms that may discourage questioning authority. Treatment adherence: Clear explanations, ongoing support, and access to peer-driven resources like social media groups and journals improve patients’ ability to follow through with treatments and manage side effects. Collaborative education: Interdisciplinary teams—including oncologists, nurses, pharmacists, social workers, and patient advocates—enhance the education process. Technology, like apps and videos, makes information more accessible and engaging. Family involvement & cultural nuance: In many communities, decision-making is collective. Patient education must account for family involvement and be adaptable to cultural norms. Measuring impact: While anecdotal benefits are strong, more structured research is needed to measure the effectiveness of educational interventions and guide best practices. Conclusion: Patient education must be embedded into cancer care, supported by trained teams and infrastructure. As one patient co-author highlights, being informed and empowered transforms the experience from passive care to active partnership.
May 15, 2025 at 4:32 PM
yvonnediaz.bsky.social
Dr @narjustflorezmd.bsky.social doesn’t shy away from tough, taboo topics. @lungevity.bsky.social #HopeSummit, she led a powerful convo on how cancer affects identity, relationships, intimacy & sexual health. Her message: you deserve care, pleasure & to feel whole.

Great party favours

#LCSM
Five female lung Cancer Patient Advocates with leading thoracic oncologist, Dr Narjust Florez Photo of Yvonne Diaz, lung Cancer Patient Advocate with leading thoracic oncologist, Dr Narjust Florez
May 6, 2025 at 6:30 PM
Reposted by Yvonne Diaz
oncogenecancer.bsky.social
Sadly cancer knows no bounds & is common around the world.

That’s why Christina, Ruth & Aude, from US, Mexico & France, will take on the @londonmarathon.bsky.social next Sunday.

All funds raised will support @icr.ac.uk’s life-saving research.

Let’s cheer them on 👇

#lcsm #LondonMarathon2025
April 21, 2025 at 10:22 AM
yvonnediaz.bsky.social
Learned loads @lungcancereurope.bsky.social AGM, like: My behaviour style is different in advocacy from my employed work. Cannot crochet. “Chemo brain” is real & applies to cancer generally. Much more. Grateful for the unexpected LuCE Patient Advocate Award. Thank you LuCE family for all.
April 13, 2025 at 4:18 PM
Reposted by Yvonne Diaz
hhorinouchi.bsky.social
⏰NOW OUT‼️#ELCC25
🔥COCOON🦋: Preventing Moderate to Severe Dermatologic Adverse Events in 1st-line EGFR-mutant Advanced NSCLC Treated with Amivantamab + Lazertinib
🎙️ Dr. Nicolas Girard
🎯AEs ≥G2: OR 0.19 (95%CI, 0.09–0.40)
✅NCT06120140
#LCSM
@oncoalert.bsky.social
@myesmo.bsky.social
@iaslc.bsky.social
March 29, 2025 at 4:06 PM
Reposted by Yvonne Diaz
narjustflorezmd.bsky.social
Our EQUAL study is open for enrollment!

More in this video!

@florezlab.bsky.social @latinasinmed.bsky.social
April 8, 2025 at 11:55 PM
Reposted by Yvonne Diaz
alkpositive.bsky.social
💬 “Palliative care isn’t about giving up—it’s about living well, longer.”

Missed our latest #ALKtalk with Dr. @lpetrillz? Catch the replay to learn how palliative care supports quality of life from day one.

🎥 Watch now: youtu.be/lz_uKKItkWc
The vital role of palliative care in ALK-positive #cancer
YouTube video by ALK Positive Inc.
youtu.be
April 9, 2025 at 1:06 PM
Reposted by Yvonne Diaz
oncogenecancer.bsky.social
Exciting to see the opening of the EQUAL study to see if we can diagnose EGFR & hopefully later other oncogene lung cancers earlier. We often don’t meet screening criteria & know that early detection saves lives. Find out more 👇

#lcsm
narjustflorezmd.bsky.social Narjust Florez, MD, FASCO @narjustflorezmd.bsky.social · Apr 8
Our EQUAL study is open for enrollment!

More in this video!

@florezlab.bsky.social @latinasinmed.bsky.social
April 9, 2025 at 11:18 AM